Solventum Corp (SOLV) Q1 2025 Earnings Call

Concluded May 8, 2025

May 8, 2025 0 turns

Period: FY2025 Q1
Runtime: —
Sources: 2 artifacts

8-K 10-Q

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.

Portfolio optimization 28 Separation from 3M and ERP 15 Health Information Systems / AI coding 14 Transform for the Future cost program 14 MedSurg segment performance 10 Q1 financial outperformance 8

Management tone

Confident

Net tone +70 · low hedging

Grounding quotes

“We delivered first quarter results ahead of our plan and ahead of expectations. Organic sales growth and EPS both exceeded our plan”
“Q1 is a clear indication that we are well on our way to delivering our 2026 guidance and, importantly, our go-forward LRP objectives”
“we see Acera as just the beginning. We have a target-rich environment for additional tuck-in acquisitions and a balance sheet that gives us the flexibility to pursue them while also returning capital to shareholders”
“given the substantial value we see in our shares and the quality of our business, one should expect that we will accelerate execution of that approval”

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Revenue $2.07B +2.7% YoY

Diluted EPS $0.78 -43.1% YoY

Gross margin 53.8% -4.3 pp YoY

Net income $137.00M -42.2% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed May 8, 2025 10-Q report Filed May 9, 2025

Quarter detail

How the reported period landed and where the business moved.

Revenue · segments

Med Surg Segment$1.16B +3.4% YoY

Health Information Systems Segment$329.00M +3.8% YoY

Dental Solutions Segment$328.00M -2.1% YoY

Purification and Filtration Segment$180.00M -26.5% YoY

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →